Use of caffeine for managing apneia of premature
DOI:
https://doi.org/10.33448/rsd-v13i5.45785Keywords:
Apnea prematurity; Caffeine; Primary treatment; Infant, premature.Abstract
Apnea of prematurity is a common diagnosis in neonatal intensive care units, especially in preterm patients under 35 weeks or patients born with low birth weight (<1500g). From this perspective, the use of caffeine citrate has short and long-term benefits in this pathology, in addition to reducing the incidence of complications. Methodology: A narrative review of the literature was carried out using the PUBMED database, using the following keywords: “Apnea Prematurity”, “Caffeine” and “Treatment”, with a 6-year filter, analyzing 164 articles, of which only 34 were included and 130 were excluded. Results and Discussion: Apnea of prematurity is a common pathology in preterm and extremely preterm infants, with an incidence of 10% of newborns after 34 weeks and 20-85% of newborns born between 30-34 weeks. The pathophysiology of the disease is explained by the immaturity of the central nervous system in maintaining respiratory drive, in addition to impaired sensitivity in response to chemoreceptors and difficulty in maintaining REM sleep, in addition to the chronic losses inherent to chronic hypoxia. Methylxanthines, the active ingredient in caffeine, have the activation mechanism of inhibiting adenosine A1 and A2 receptors coupled to G protein. The recommended initial dose for therapy is 10 mg/kg for apnea of prematurity, but it must be monitored with concentrations serum levels of the drug to a safe therapeutic range, in addition to monitoring side effects in view of the patient's clinical impairment. The main signs of side effects from the use of caffeine are tachycardia, hyperglycemia, reduced growth rate, jaundice, irritability, agitation and convulsions. Conclusion: Apnea of prematurity is a very prevalent pathology in preterm newborns and its therapeutic possibility must be taken into account in view of its possible short and long-term complications, since the use of methylxanthines has different evidence of clinical improvement.
References
Alhersh, E., Abushanab, D., Al-Shaibi, S., & Al-Badriyeh, D. (2020). Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses. Paediatric Drugs, 22(4), 399–408. https://doi.org/10.1007/s40272-020-00404-4
Chen, J., Jin, L., & Chen, X. (2018). Efficacy and Safety of Different Maintenance Doses of Caffeine Citrate for Treatment of Apnea in Premature Infants: A Systematic Review and Meta-Analysis. BioMed Research International, 2018, 1–11. https://doi.org/10.1155/2018/9061234
Dai, H.-R., Guo, H.-L., Hu, Y.-H., Xu, J., Ding, X.-S., Cheng, R., & Chen, F. (2022). Precision caffeine therapy for apnea of prematurity and circadian rhythms: New possibilities open up. Frontiers in Pharmacology, 13, 1053210. https://doi.org/10.3389/fphar.2022.1053210
Du, L., Tong, X., Chen, C., Gao, X., Gagnatelli, A., Li, J., Santoro, D., Nicolardi, S., & Fabbri, L. (2020). Caffeine Citrate for Apnea of Prematurity: A Prospective, Open-Label, Single-Arm Study in Chinese Neonates. Frontiers in Pediatrics, 8. https://doi.org/10.3389/fped.2020.00076
Elmowafi, M., Mohsen, N., Nour, I., & Nasef, N. (2021). Prophylactic versus therapeutic caffeine for apnea of prematurity: a randomized controlled trial. The Journal of Maternal-Fetal & Neonatal Medicine, 1–9. https://doi.org/10.1080/14767058.2021.1904873
Guo, A., Zhu, Z., Xue, J., Di, X., Fan, J., Huang, L., Zhao, P., Hu, X., & Xie, H. (2020). Population pharmacokinetic study of caffeine citrate in Chinese premature infants with apnea. Journal of Clinical Pharmacy and Therapeutics, 45(6), 1414–1421. https://doi.org/10.1111/jcpt.13240
Guo, H.-L., Long, J.-Y., Hu, Y.-H., Liu, Y., He, X., Li, L., Xia, Y., Ding, X.-S., Chen, F., Xu, J., & Cheng, R. (2022). Caffeine Therapy for Apnea of Prematurity: Role of the Circadian CLOCK Gene Polymorphism. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.724145
He, T., Liao, Z. C., Ding, Y., Wang, M. J., Li, W., Gan, J. M., & Yue, S. J. (2020). Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 22(7), 684–689. https://doi.org/10.7499/j.issn.1008-8830.2003276
He, X., Qiu, J.-C., Lu, K.-Y., Guo, H.-L., Li, L., Jia, W.-W., Ni, M.-M., Liu, Y., Xu, J., Chen, F., & Cheng, R. (2020). Therapy for Apnoea of Prematurity: A Retrospective Study on Effects of Standard Dose and Genetic Variability on Clinical Response to Caffeine Citrate in Chinese Preterm Infants. Advances in Therapy, 38(1), 607–626. https://doi.org/10.1007/s12325-020-01544-2
Irimu, G., Okwaro, F., Coleman, J., Waiyego, M., Murila, F., Chomba, D., Parsimei, M., Shitote, C., Ochieng, R., Shah, J., Ogero, M., Amy Sarah Ginsburg, J. Mark Ansermino, & Macharia, W. (2023). Developing and testing a clinical care bundle incorporating caffeine citrate to manage apnoea of prematurity in a resource-constrained setting: a mixed methods clinical feasibility study protocol. Implementation Science Communications, 4(1). https://doi.org/10.1186/s43058-023-00455-x
Kelly, C. E., Wenn Lynn Ooi, Joseph Yuan-Mou Yang, Chen, J., Adamson, C., Lee, K. J., Jeanie L.Y. Cheong, Anderson, P. J., Doyle, L. W., & Thompson, D. K. (2018). Caffeine for apnea of prematurity and brain development at 11 years of age. Annals of Clinical and Translational Neurology, 5(9), 1112–1127. https://doi.org/10.1002/acn3.628
Kori, Hans Van Rostenberghe, Nor Rosidah Ibrahim, Najib Majdi Yaacob, & Nasir, A. (2021). A Randomized Controlled Trial Comparing Two Doses of Caffeine for Apnoea in Prematurity. International Journal of Environmental Research and Public Health, 18(9), 4509–4509. https://doi.org/10.3390/ijerph18094509
Laouafa, S., Iturri, P., Arias-Reyes, C., Marcouiller, F., Gonzales, M., Joseph, V., Bairam, A., & Soliz, J. (2019). Erythropoietin and caffeine exert similar protective impact against neonatal intermittent hypoxia: Apnea of prematurity and sex dimorphism. Experimental Neurology, 320, 112985. https://doi.org/10.1016/j.expneurol.2019.112985
Lin, Y.-C., Tan, Y.-L., Yen, T.-A., Chen, C.-Y., Tsao, P.-N., & Chou, H.-C. (2022). Specific Premature Groups Have Better Benefits When Treating Apnea With Caffeine Than Aminophylline/Theophylline. Frontiers in Pediatrics, 10. https://doi.org/10.3389/fped.2022.817624
Long, J.-Y., Guo, H.-L., He, X., Hu, Y.-H., Xia, Y., Cheng, R., Ding, X.-S., Chen, F., & Xu, J. (2021). Caffeine for the Pharmacological Treatment of Apnea of Prematurity in the NICU: Dose Selection Conundrum, Therapeutic Drug Monitoring and Genetic Factors. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.681842
McDonald, F. B., Dempsey, E. M., & O’Halloran, K. D. (2018). Caffeine therapy for apnoea of prematurity: Wake up to the fact that sex matters. Experimental Physiology, 103(10), 1294–1295. https://doi.org/10.1113/ep087222
Miao, Y., Liu, W., Zhao, S., Li, Y., Jiang, H., Wang, A., Teng, P., & Zhang, Y. (2023). Effect of prophylactic caffeine in the treatment of apnea in very low birth weight infants: a meta-analysis. Journal of Maternal-Fetal & Neonatal Medicine, 36(1). https://doi.org/10.1080/14767058.2023.2214659
Miao, Y., Zhou, Y., Zhao, S., Liu, W., Wang, A., Zhang, Y., Li, Y., & Jiang, H. (2022). Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis. PLOS ONE, 17(9), e0274882. https://doi.org/10.1371/journal.pone.0274882
Mürner-Lavanchy, I. M., Doyle, L. W., Schmidt, B., Roberts, R. S., Asztalos, E. V., Costantini, L., Davis, P. G., Dewey, D., D’Ilario, J., Grunau, R. E., Moddemann, D., Nelson, H., Ohlsson, A., Solimano, A., Tin, W., & Anderson, P. J. (2018). Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity. Pediatrics, 141(5), e20174047. https://doi.org/10.1542/peds.2017-4047
N. Heuzé, Goyer, I., F. Porcheret, Denis, M., C. Faucon, Jokic, M., & D. Brossier. (2020). Caffeine treatment for bronchiolitis-related apnea in the pediatric intensive care unit. Archives de Pédiatrie, 27(1), 18–23. https://doi.org/10.1016/j.arcped.2019.10.009
Nagasato, A., Nakamura, M., & Kamimura, H. (2018). Comparative Study of the Efficacy and Safety of Caffeine and Aminophylline for the Treatment of Apnea in Preterm Infants. Yakugaku Zasshi, 138(2), 237–242. https://doi.org/10.1248/yakushi.17-00144
Philip, R. K., Ismail, A., Murphy, B., Mirza, A., Quinn, C., & Dunworth, M. (2018). Caffeine Treatment for Apnea of Prematurity and the Influence on Dose-Dependent Postnatal Weight Gain Observed Over 15 Years. Journal of Caffeine and Adenosine Research, 8(3), 99–106. https://doi.org/10.1089/caff.2018.0005
Rebentisch, A., Kovey, K., & Denslow, S. (2021). An Evaluation of Twice-Daily Dosing of Caffeine for Apnea of Prematurity. The Journal of Pediatric Pharmacology and Therapeutics, 26(3), 253–257. https://doi.org/10.5863/1551-6776-26.3.253
Rosen, C., Taran, C., Hanna, M., Gueta, I., Loebstein, R., Strauss, T., & Yarden-Bilavsky, H. (2021). Caffeine citrate for apnea of prematurity—One dose does not fit all a prospective study. Journal of Perinatology, 41(9), 2292–2297. https://doi.org/10.1038/s41372-021-01172-w
Rother, E. T. (2007). Systematic literature review X narrative review. Acta Paulista de Enfermagem, 20(2), v–vi. https://doi.org/10.1590/s0103- 21002007000200001
Schmidt, B., Anderson, P. J., Asztalos, E. V., Doyle, L. W., Grunau, R. E., Moddemann, D., & Roberts, R. S. (2019). Self-reported Quality of Life at Middle School Age in Survivors of Very Preterm Birth. JAMA Pediatrics, 173(5), 487–487. https://doi.org/10.1001/jamapediatrics.2018.4853
Shah, A. S., Leu, R. M., Shah, S. P., Martinez, F., & Kasi, A. S. (2023). Images: Caffeine therapy for central sleep apnea, hypoxemia, and hypoventilation in a term neonate. Journal of Clinical Sleep Medicine, 19(5), 1005–1008. https://doi.org/10.5664/jcsm.10504
Snyder, H. (2019). Literature Review as a Research methodology: an Overview and Guidelines. Journal of Business Research, 104(1), 333–339. https://doi.org/10.1016/j.jbusres.2019.07.039
Vliegenthart, R., Miedema, M., Hutten, G. J., Kaam, A. H. van, & Onland, W. (2018). High versus standard dose caffeine for apnoea: a systematic review. Archives of Disease in Childhood - Fetal and Neonatal Edition, 103(6), F523–F529. https://doi.org/10.1136/archdischild-2017-313556
Williamson, M., Poorun, R., & Hartley, C. (2021). Apnoea of Prematurity and Neurodevelopmental Outcomes: Current Understanding and Future Prospects for Research. Frontiers in Pediatrics, 9. https://doi.org/10.3389/fped.2021.755677
Xie, J.-B., & Lin, X.-Z. (2022). [Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity]. PubMed, 24(7), 832–837. https://doi.org/10.7499/j.issn.1008-8830.2203134
Yun, W. Z., Kassab, Y. W., Yao, L. M., Khairuddin, N., Ming, L. C., & Hadi, M. A. (2022). Effectiveness and safety of early versus late caffeine therapy in managing apnoea of prematurity among preterm infants: a retrospective cohort study. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-022-01437-0
Zahra Fakoor, Ali Aghayar Makooie, Zahra Joudi, & Rasool Gharaaghaji Asl. (2019). The effect of venous caffeine on the prevention of apnea of prematurity in the very preterm infants in the neonatal intensive care unit of Shahid Motahhari Hospital, Urmia, during a year. Journal of Advanced Pharmaceutical Technology & Research, 10(1), 16–16. https://doi.org/10.4103/japtr.japtr_334_18
Zhang, C.-Y., Liu, D., Hua, S.-D., Guo, S., Li, X.-Y., Zhang, B., & An, L.-H. (2020). Caffeine versus aminophylline in combination with oxygen therapy for apnea of prematurity: A retrospective cohort study. Experimental and Therapeutic Medicine, 20(5), 1–1. https://doi.org/10.3892/etm.2020.9175
Zhang, X., Zhang, H. T., Lyu, Y., Wang, L. F., & Yang, Z. Y. (2019). Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 21(6), 558–561. https://doi.org/10.7499/j.issn.1008-8830.2019.06.011
Zulqarnain, A., Hussain, M., Suleri, K. M., & Ali Ch., Z. (2019). Comparison of Caffeine versus Theophylline for apnea of prematurity. Pakistan Journal of Medical Sciences, 35(1). https://doi.org/10.12669/pjms.35.1.94
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 José de Ribamar Barroso Jucá Neto; Lívia Fontelles Brasil; Letícia Martins de Mendonça; Thiago Rocha Mapurunga; Emanuelle Cordova de Souza; Pedro Iughetti Morais; Ângela Rocha Mapurunga
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
